Animal models for hepatocellular carcinoma

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):993-1002. doi: 10.1016/j.bbadis.2018.08.009. Epub 2018 Aug 10.

Abstract

Hepatocellular carcinoma (HCC) represents ~90% of all cases of primary liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Establishing appropriate animal models for HCC is required for basic and translational studies, especially the models that can recapitulate one of the human disease settings. Current animal models can be categorized as chemically-induced, genetically-engineered, xenograft, or a combination of these with each other or with a metabolic insult. A single approach to resemble human HCC in animals is not sufficient. Combining pathogenic insults in animal models may more realistically recapitulate the multiple etiologic agents occurring in humans. Combining chemical injury with metabolic disorder or alcohol consumption in mice reduces the time taken to hepatocarcinogenesis. Genetically-engineering weak activation of HCC-promoting pathways combined with disease-specific injury models will possibly mimic the pathophysiology of human HCC in distinct clinical settings.

Keywords: Animal model; Chemical; Genetically engineered mouse; Hepatocellular carcinoma; Xenograft.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carbon Tetrachloride / toxicity
  • Carcinoma, Hepatocellular / etiology*
  • Carcinoma, Hepatocellular / pathology
  • Disease Models, Animal*
  • Gene Editing / methods
  • Humans
  • Liver Neoplasms / etiology*
  • Liver Neoplasms / pathology
  • Xenograft Model Antitumor Assays / methods

Substances

  • Carbon Tetrachloride